Mad for it
MAD World Summit 2026 has secured official accreditation from The CPD Group
Read More
Author: John Pinching
Microbiotica presents phase 1b data for MB097 at ESMO 2026
Early responses suggest restored sensitivity to anti‑PD‑1 therapy
Read More
FDA approves Hibsago for chronic hepatitis B
First-in-class therapy offers functional cure potential
Read More
FDA approves Enspryng for at‑home TED treatment
First SC option offers new flexibility for patients
Read More
EU approves teclistamab monotherapy for earlier myeloma use
Second-line authorisation expands immunotherapy options
Read More
